These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17970580)

  • 1. [3/3 Inhibitors of mTOR (sirolimus and everolimus)].
    Chaumard N; Limat S; Woronoff-Lemsi MC
    Soins; 2007 Sep; (718):63-4. PubMed ID: 17970580
    [No Abstract]   [Full Text] [Related]  

  • 2. Everolimus and mTOR inhibitors in liver transplantation: opening the "box".
    Everson GT
    Liver Transpl; 2006 Nov; 12(11):1571-3. PubMed ID: 17058246
    [No Abstract]   [Full Text] [Related]  

  • 3. Sirolimus to replace calcineurin inhibitors? Too early yet.
    Cravedi P; Ruggenenti P; Remuzzi G
    Lancet; 2009 Apr; 373(9671):1235-6. PubMed ID: 19362662
    [No Abstract]   [Full Text] [Related]  

  • 4. Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.
    Zuckermann A; Manito N; Epailly E; Fiane A; Bara C; Delgado JF; Lehmkuhl H; Ross H; Eisen H; Chapman J; Valantine H
    J Heart Lung Transplant; 2008 Feb; 27(2):141-9. PubMed ID: 18267219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommendations for the use of everolimus (Certican) in heart transplantation: results from the second German-Austrian Certican Consensus Conference.
    Rothenburger M; Zuckermann A; Bara C; Hummel M; Strüber M; Hirt S; Lehmkuhl H;
    J Heart Lung Transplant; 2007 Apr; 26(4):305-11. PubMed ID: 17403469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA; Heizer KE
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma.
    Oudard S; Medioni J; Aylllon J; Barrascourt E; Elaidi RT; Balcaceres J; Scotte F
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):705-17. PubMed ID: 19496707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pleiotropic effects of mTor inhibitors.
    Ponticelli C
    J Nephrol; 2004; 17(6):762-8. PubMed ID: 15593048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sirolimus in renal transplantation.
    Morath C; Arns W; Schwenger V; Mehrabi A; Fonouni H; Schmidt J; Zeier M
    Nephrol Dial Transplant; 2007 Sep; 22 Suppl 8():viii61-viii65. PubMed ID: 17890266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview.
    Huyghe E; Zairi A; Nohra J; Kamar N; Plante P; Rostaing L
    Transpl Int; 2007 Apr; 20(4):305-11. PubMed ID: 17326771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of symposium. Sirolimus in kidney transplantation.
    Schena FP
    Transplantation; 2009 Apr; 87(8 Suppl):S30-3. PubMed ID: 19384185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Everolimus: immunosuppression with antilymphoproliferative therapy].
    Pascual J
    Nefrologia; 2004; 24(2):112-23. PubMed ID: 15219086
    [No Abstract]   [Full Text] [Related]  

  • 14. mTOR inhibitors and their secondary effects in cardiac transplant recipients: a descriptive study.
    Moro J; Almenar L; Martínez-Dolz L; Izquierdo M; Rueda J; Arnau MA; Agüero J; Sánchez-Lázaro I; Ortiz V; Salvador A
    Transplant Proc; 2007 Sep; 39(7):2365-7. PubMed ID: 17889191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switch to everolimus for sirolimus-induced pneumonitis in a liver transplant recipient--not all proliferation signal inhibitors are the same: a case report.
    De Simone P; Petruccelli S; Precisi A; Carrai P; Doria R; Menichetti F; Filipponi F
    Transplant Proc; 2007 Dec; 39(10):3500-1. PubMed ID: 18089420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
    Pascual J
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T; Mis L; Hammond JM
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens.
    Millán O; Jiménez O; Fortuna V; Barceló JJ; Brunet M
    Int J Immunopathol Pharmacol; 2006; 19(2):317-30. PubMed ID: 16831299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sirolimus-induced aphthous ulcers which disappeared with conversion to everolimus.
    Ram R; Swarnalatha G; Neela P; Dakshinamurty KV
    Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):819-20. PubMed ID: 18711306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.